SPIA
IMDX

Steward Partners Investment Advisory’s Insight Molecular Diagnostics IMDX Stock Holding History

Steward Partners Investment Advisory’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6K Buy
+1,960
New +$9.67K ﹤0.01% 3667

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Steward Partners Investment Advisory's IMDX Position: Q2 2026 in Review

Steward Partners Investment Advisory opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 1,960 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #3667 among its holdings.

35 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Steward Partners Investment Advisory held 1,960 shares of Insight Molecular Diagnostics worth $11.6K as of Q2 2026.
  • Insight Molecular Diagnostics was a new Steward Partners Investment Advisory position in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3667 holding.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.